MAP2K7 and acute myeloid leukemia: Mechanistically, the inactivation of TP53 leads to the activation of the Ras/Raf/MEK/ERK pathway and, therefore, the inactivation of GSK3, preventing phosphorylation-dependent degradation of MCL1 in AML [55].